Vuddhakul V, Mai G T, McCormack J G, Seow W K, Thong Y H
Department of Child Health, University of Queensland, Mater Public Hospital, South Brisbane, Australia.
Int J Immunopharmacol. 1990;12(6):639-45. doi: 10.1016/0192-0561(90)90101-r.
Itraconazole and fluconazole are triazole compounds recently licensed for the therapy of systemic fungal infections. At 10 micrograms/ml concentrations, itraconazole was found to suppress neutrophil chemotaxis, random movement, deoxyglucose uptake and hexose-monophosphate shunt activity to the same extent as ketoconazole, an older generation azole antifungal. Itraconazole was also found to suppress mitogen-induced lymphocyte transformation to the same extent as ketoconazole at concentrations as low as 1 microgram/ml. By contrast, significant inhibition of both neutrophil and lymphocyte functions was not observed with fluconazole at concentrations as high as 50 micrograms/ml. These results suggest that fluconazole may be less immunotoxic than itraconazole, and may be more suitable for use in immunocompromised patients.
伊曲康唑和氟康唑是最近被批准用于治疗全身性真菌感染的三唑类化合物。在浓度为10微克/毫升时，发现伊曲康唑抑制中性粒细胞趋化性、随机运动、脱氧葡萄糖摄取和己糖磷酸分流活性的程度与酮康唑（一种较老一代的唑类抗真菌药）相同。还发现伊曲康唑在低至1微克/毫升的浓度下抑制丝裂原诱导的淋巴细胞转化的程度与酮康唑相同。相比之下，在高达50微克/毫升的浓度下，氟康唑未观察到对中性粒细胞和淋巴细胞功能的显著抑制。这些结果表明，氟康唑的免疫毒性可能比伊曲康唑小，可能更适合用于免疫功能低下的患者。
